APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bronchitis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Bronchitis Drug Industry Research Report 2026

22 December 2025126 pages

Choose your research edition.

Industry ResearchBronchitis Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Bronchitis Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Bronchitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bronchitis Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Bronchitis Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Bronchitis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Bronchitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Bronchitis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Bronchitis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Bronchitis Drug include Merck & Co Inc, AstraZeneca Plc, Therabron Therapeutics Inc, Orbis Biosciences Inc, Mucosis BV, Kyorin Pharmaceutical Co Ltd, Han Wha Pharma Co Ltd, F. Hoffmann-La Roche Ltd and DBV Technologies SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Bronchitis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Bronchitis Drug Market by Company

Merck & Co Inc

AstraZeneca Plc

Therabron Therapeutics Inc

Orbis Biosciences Inc

Mucosis BV

Kyorin Pharmaceutical Co Ltd

Han Wha Pharma Co Ltd

F. Hoffmann-La Roche Ltd

DBV Technologies SA

Advanced Inhalation Therapies (AIT) Ltd

Bronchitis Drug Segment by Type

AZD-9668

CG-367

HOB-051

Cyclosporine

Others

Bronchitis Drug Segment by Application

Clinic

Hospital

Homecare

Bronchitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bronchitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bronchitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bronchitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Bronchitis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Bronchitis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Bronchitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Bronchitis Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Bronchitis Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Bronchitis Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Bronchitis Drug Revenue of Manufacturers (2021-2026) Table 9. Global Bronchitis Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Bronchitis Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Bronchitis Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Bronchitis Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Bronchitis Drug, Product Type & Application Table 14. Global Bronchitis Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Bronchitis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Merck & Co Inc Company Information Table 19. Merck & Co Inc Business Overview Table 20. Merck & Co Inc Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Merck & Co Inc Bronchitis Drug Product Portfolio Table 22. Merck & Co Inc Recent Developments Table 23. AstraZeneca Plc Company Information Table 24. AstraZeneca Plc Business Overview Table 25. AstraZeneca Plc Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. AstraZeneca Plc Bronchitis Drug Product Portfolio Table 27. AstraZeneca Plc Recent Developments Table 28. Therabron Therapeutics Inc Company Information Table 29. Therabron Therapeutics Inc Business Overview Table 30. Therabron Therapeutics Inc Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Therabron Therapeutics Inc Bronchitis Drug Product Portfolio Table 32. Therabron Therapeutics Inc Recent Developments Table 33. Orbis Biosciences Inc Company Information Table 34. Orbis Biosciences Inc Business Overview Table 35. Orbis Biosciences Inc Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Orbis Biosciences Inc Bronchitis Drug Product Portfolio Table 37. Orbis Biosciences Inc Recent Developments Table 38. Mucosis BV Company Information Table 39. Mucosis BV Business Overview Table 40. Mucosis BV Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Mucosis BV Bronchitis Drug Product Portfolio Table 42. Mucosis BV Recent Developments Table 43. Kyorin Pharmaceutical Co Ltd Company Information Table 44. Kyorin Pharmaceutical Co Ltd Business Overview Table 45. Kyorin Pharmaceutical Co Ltd Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Kyorin Pharmaceutical Co Ltd Bronchitis Drug Product Portfolio Table 47. Kyorin Pharmaceutical Co Ltd Recent Developments Table 48. Han Wha Pharma Co Ltd Company Information Table 49. Han Wha Pharma Co Ltd Business Overview Table 50. Han Wha Pharma Co Ltd Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Han Wha Pharma Co Ltd Bronchitis Drug Product Portfolio Table 52. Han Wha Pharma Co Ltd Recent Developments Table 53. F. Hoffmann-La Roche Ltd Company Information Table 54. F. Hoffmann-La Roche Ltd Business Overview Table 55. F. Hoffmann-La Roche Ltd Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. F. Hoffmann-La Roche Ltd Bronchitis Drug Product Portfolio Table 57. F. Hoffmann-La Roche Ltd Recent Developments Table 58. DBV Technologies SA Company Information Table 59. DBV Technologies SA Business Overview Table 60. DBV Technologies SA Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. DBV Technologies SA Bronchitis Drug Product Portfolio Table 62. DBV Technologies SA Recent Developments Table 63. Advanced Inhalation Therapies (AIT) Ltd Company Information Table 64. Advanced Inhalation Therapies (AIT) Ltd Business Overview Table 65. Advanced Inhalation Therapies (AIT) Ltd Bronchitis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Advanced Inhalation Therapies (AIT) Ltd Bronchitis Drug Product Portfolio Table 67. Advanced Inhalation Therapies (AIT) Ltd Recent Developments Table 68. Global Bronchitis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Bronchitis Drug Sales by Region (2021-2026) & (k units) Table 70. Global Bronchitis Drug Sales Market Share by Region (2021-2026) Table 71. Global Bronchitis Drug Sales by Region (2027-2032) & (k units) Table 72. Global Bronchitis Drug Sales Market Share by Region (2027-2032) Table 73. Global Bronchitis Drug Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Bronchitis Drug Revenue Market Share by Region (2021-2026) Table 75. Global Bronchitis Drug Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Bronchitis Drug Revenue Market Share by Region (2027-2032) Table 77. North America Bronchitis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Bronchitis Drug Sales by Country (2021-2026) & (k units) Table 79. North America Bronchitis Drug Sales by Country (2027-2032) & (k units) Table 80. North America Bronchitis Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Bronchitis Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Bronchitis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Bronchitis Drug Sales by Country (2021-2026) & (k units) Table 84. Europe Bronchitis Drug Sales by Country (2027-2032) & (k units) Table 85. Europe Bronchitis Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Bronchitis Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Bronchitis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Bronchitis Drug Sales by Country (2021-2026) & (k units) Table 89. Asia Pacific Bronchitis Drug Sales by Country (2027-2032) & (k units) Table 90. Asia Pacific Bronchitis Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Bronchitis Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Bronchitis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Bronchitis Drug Sales by Country (2021-2026) & (k units) Table 94. South America Bronchitis Drug Sales by Country (2027-2032) & (k units) Table 95. South America Bronchitis Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Bronchitis Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Bronchitis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Bronchitis Drug Sales by Country (2021-2026) & (k units) Table 99. Middle East and Africa Bronchitis Drug Sales by Country (2027-2032) & (k units) Table 100. Middle East and Africa Bronchitis Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Bronchitis Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Bronchitis Drug Sales by Type (2021-2026) & (k units) Table 103. Global Bronchitis Drug Sales by Type (2027-2032) & (k units) Table 104. Global Bronchitis Drug Sales Market Share by Type (2021-2026) Table 105. Global Bronchitis Drug Sales Market Share by Type (2027-2032) Table 106. Global Bronchitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Bronchitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Bronchitis Drug Revenue Market Share by Type (2021-2026) Table 109. Global Bronchitis Drug Revenue Market Share by Type (2027-2032) Table 110. Global Bronchitis Drug Price by Type (2021-2026) & (US$/unit) Table 111. Global Bronchitis Drug Price by Type (2027-2032) & (US$/unit) Table 112. Global Bronchitis Drug Sales by Application (2021-2026) & (k units) Table 113. Global Bronchitis Drug Sales by Application (2027-2032) & (k units) Table 114. Global Bronchitis Drug Sales Market Share by Application (2021-2026) Table 115. Global Bronchitis Drug Sales Market Share by Application (2027-2032) Table 116. Global Bronchitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Bronchitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Bronchitis Drug Revenue Market Share by Application (2021-2026) Table 119. Global Bronchitis Drug Revenue Market Share by Application (2027-2032) Table 120. Global Bronchitis Drug Price by Application (2021-2026) & (US$/unit) Table 121. Global Bronchitis Drug Price by Application (2027-2032) & (US$/unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Bronchitis Drug Distributors List Table 125. Bronchitis Drug Customers List Table 126. Bronchitis Drug Industry Trends Table 127. Bronchitis Drug Industry Drivers Table 128. Bronchitis Drug Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Bronchitis Drug Product Image Figure 5. Global Bronchitis Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Bronchitis Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Bronchitis Drug Sales (2021-2032) & (k units) Figure 8. Global Bronchitis Drug Average Price (US$/unit) & (2021-2032) Figure 9. AZD-9668 Product Image Figure 10. CG-367 Product Image Figure 11. HOB-051 Product Image Figure 12. Cyclosporine Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Homecare Product Image Figure 17. Global Bronchitis Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Bronchitis Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Bronchitis Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Bronchitis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Bronchitis Drug Sales by Region in 2025 Figure 23. Global Bronchitis Drug Revenue by Region in 2025 Figure 24. North America Bronchitis Drug Market Size by Country in 2025 Figure 25. North America Bronchitis Drug Sales Market Share by Country (2021-2032) Figure 26. North America Bronchitis Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Bronchitis Drug Market Size by Country in 2025 Figure 31. Europe Bronchitis Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Bronchitis Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Bronchitis Drug Market Size by Country in 2025 Figure 44. Asia Pacific Bronchitis Drug Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Bronchitis Drug Revenue Market Share by Country (2021-2032) Figure 46. China Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Bronchitis Drug Market Size by Country in 2025 Figure 55. South America Bronchitis Drug Sales Market Share by Country (2021-2032) Figure 56. South America Bronchitis Drug Revenue Market Share by Country (2021-2032) Figure 57. Brazil Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Bronchitis Drug Market Size by Country in 2025 Figure 62. Middle East and Africa Bronchitis Drug Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Bronchitis Drug Revenue Market Share by Country (2021-2032) Figure 64. Egypt Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Bronchitis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Bronchitis Drug Sales Market Share by Type (2021-2032) Figure 70. Global Bronchitis Drug Revenue Market Share by Type (2021-2032) Figure 71. Global Bronchitis Drug Price (US$/unit) by Type (2021-2032) Figure 72. Global Bronchitis Drug Sales Market Share by Application (2021-2032) Figure 73. Global Bronchitis Drug Revenue Market Share by Application (2021-2032) Figure 74. Global Bronchitis Drug Price (US$/unit) by Application (2021-2032) Figure 75. Bronchitis Drug Value Chain Figure 76. Bronchitis Drug Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Bronchitis Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • AZD-9668
  • CG-367
  • HOB-051
  • Cyclosporine
  • Others
Applications
  • Clinic
  • Hospital
  • Homecare
Companies covered
  • Merck & Co Inc
  • AstraZeneca Plc
  • Therabron Therapeutics Inc
  • Orbis Biosciences Inc
  • Mucosis BV
  • Kyorin Pharmaceutical Co Ltd
  • Han Wha Pharma Co Ltd
  • F. Hoffmann-La Roche Ltd
  • DBV Technologies SA
  • Advanced Inhalation Therapies (AIT) Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Bronchitis Drug Market Size (2021-2032)
  4. 2.2.2 Global Bronchitis Drug Sales (2021-2032)
  5. 2.2.3 Global Bronchitis Drug Market Average Price (2021-2032)
  6. 2.3 Bronchitis Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 AZD-9668
  9. 2.3.3 CG-367
  10. 2.3.4 HOB-051
  11. 2.3.5 Cyclosporine
  12. 2.3.6 Others
  13. 2.4 Bronchitis Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Homecare
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Bronchitis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Bronchitis Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Bronchitis Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Bronchitis Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Bronchitis Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Bronchitis Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Bronchitis Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Bronchitis Drug, Established Date
  9. 3.9 Global Bronchitis Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Merck & Co Inc
  2. 4.1.1 Merck & Co Inc Company Information
  3. 4.1.2 Merck & Co Inc Business Overview
  4. 4.1.3 Merck & Co Inc Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Merck & Co Inc Bronchitis Drug Product Portfolio
  6. 4.1.5 Merck & Co Inc Recent Developments
  7. 4.2 AstraZeneca Plc
  8. 4.2.1 AstraZeneca Plc Company Information
  9. 4.2.2 AstraZeneca Plc Business Overview
  10. 4.2.3 AstraZeneca Plc Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 AstraZeneca Plc Bronchitis Drug Product Portfolio
  12. 4.2.5 AstraZeneca Plc Recent Developments
  13. 4.3 Therabron Therapeutics Inc
  14. 4.3.1 Therabron Therapeutics Inc Company Information
  15. 4.3.2 Therabron Therapeutics Inc Business Overview
  16. 4.3.3 Therabron Therapeutics Inc Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Therabron Therapeutics Inc Bronchitis Drug Product Portfolio
  18. 4.3.5 Therabron Therapeutics Inc Recent Developments
  19. 4.4 Orbis Biosciences Inc
  20. 4.4.1 Orbis Biosciences Inc Company Information
  21. 4.4.2 Orbis Biosciences Inc Business Overview
  22. 4.4.3 Orbis Biosciences Inc Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Orbis Biosciences Inc Bronchitis Drug Product Portfolio
  24. 4.4.5 Orbis Biosciences Inc Recent Developments
  25. 4.5 Mucosis BV
  26. 4.5.1 Mucosis BV Company Information
  27. 4.5.2 Mucosis BV Business Overview
  28. 4.5.3 Mucosis BV Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mucosis BV Bronchitis Drug Product Portfolio
  30. 4.5.5 Mucosis BV Recent Developments
  31. 4.6 Kyorin Pharmaceutical Co Ltd
  32. 4.6.1 Kyorin Pharmaceutical Co Ltd Company Information
  33. 4.6.2 Kyorin Pharmaceutical Co Ltd Business Overview
  34. 4.6.3 Kyorin Pharmaceutical Co Ltd Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kyorin Pharmaceutical Co Ltd Bronchitis Drug Product Portfolio
  36. 4.6.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  37. 4.7 Han Wha Pharma Co Ltd
  38. 4.7.1 Han Wha Pharma Co Ltd Company Information
  39. 4.7.2 Han Wha Pharma Co Ltd Business Overview
  40. 4.7.3 Han Wha Pharma Co Ltd Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Han Wha Pharma Co Ltd Bronchitis Drug Product Portfolio
  42. 4.7.5 Han Wha Pharma Co Ltd Recent Developments
  43. 4.8 F. Hoffmann-La Roche Ltd
  44. 4.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 4.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 4.8.3 F. Hoffmann-La Roche Ltd Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 F. Hoffmann-La Roche Ltd Bronchitis Drug Product Portfolio
  48. 4.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 4.9 DBV Technologies SA
  50. 4.9.1 DBV Technologies SA Company Information
  51. 4.9.2 DBV Technologies SA Business Overview
  52. 4.9.3 DBV Technologies SA Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 DBV Technologies SA Bronchitis Drug Product Portfolio
  54. 4.9.5 DBV Technologies SA Recent Developments
  55. 4.10 Advanced Inhalation Therapies (AIT) Ltd
  56. 4.10.1 Advanced Inhalation Therapies (AIT) Ltd Company Information
  57. 4.10.2 Advanced Inhalation Therapies (AIT) Ltd Business Overview
  58. 4.10.3 Advanced Inhalation Therapies (AIT) Ltd Bronchitis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Advanced Inhalation Therapies (AIT) Ltd Bronchitis Drug Product Portfolio
  60. 4.10.5 Advanced Inhalation Therapies (AIT) Ltd Recent Developments
5 Global Bronchitis Drug Market Scenario by Region
  1. 5.1 Global Bronchitis Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Bronchitis Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Bronchitis Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Bronchitis Drug Sales by Region: 2027-2032
  5. 5.3 Global Bronchitis Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Bronchitis Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Bronchitis Drug Revenue by Region: 2027-2032
  8. 5.4 North America Bronchitis Drug Market Facts & Figures by Country
  9. 5.4.1 North America Bronchitis Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Bronchitis Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Bronchitis Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Bronchitis Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Bronchitis Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Bronchitis Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Bronchitis Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Bronchitis Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Bronchitis Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Bronchitis Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Bronchitis Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Bronchitis Drug Market Facts & Figures by Country
  41. 5.7.1 South America Bronchitis Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Bronchitis Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Bronchitis Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Bronchitis Drug Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Bronchitis Drug Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Bronchitis Drug Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Bronchitis Drug Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Bronchitis Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Bronchitis Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Bronchitis Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Bronchitis Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Bronchitis Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Bronchitis Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Bronchitis Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Bronchitis Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Bronchitis Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Bronchitis Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Bronchitis Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Bronchitis Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Bronchitis Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Bronchitis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Bronchitis Drug Value Chain Analysis
  2. 8.1.1 Bronchitis Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Bronchitis Drug Production Mode & Process
  5. 8.2 Bronchitis Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Bronchitis Drug Distributors
  8. 8.2.3 Bronchitis Drug Customers
9 Global Bronchitis Drug Analyzing Market Dynamics
  1. 9.1 Bronchitis Drug Industry Trends
  2. 9.2 Bronchitis Drug Industry Drivers
  3. 9.3 Bronchitis Drug Industry Opportunities and Challenges
  4. 9.4 Bronchitis Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst